Readline

About Readline

Established in 2017, Shenzhen Readline Biotech Co., Ltd. is a bio-pharmaceutical enterprise leveraging synthetic biotechnology, with a core focus on enzyme catalysis. The company has positioned itself as a key manufacturer of active ingredients for the cosmetics, nutritional supplements, and pharmaceutical sectors. Readline's business model is centered on the green, large-scale production of active pharmaceutical ingredients (APIs), including peptides, carbohydrates, proteins, and nucleic acids. These components are supplied to a global client base in industries such as medicine, healthcare, cosmetics, animal health, and green agriculture.

Readline operates a proprietary platform named "ReBioHub," which integrates biocomputing, artificial intelligence, enzyme engineering, and green chemistry. This system facilitates the development and manufacturing of functional raw materials. The company's products are categorized into six series: effective skincare, nutrition and health, animal health, biomedicine, green agriculture, and biomaterials. Notable products include β-Nicotinamide mononucleotide (NMN), semaglutide for research and development purposes, myostatin, and collagen tripeptide. Revenue is primarily generated through the provision of its synthetic biotechnology application services.

The company was founded in Shenzhen, China, and has expanded its operational footprint with bases in Zhuhai, Gansu, and the UK. A significant milestone was the establishment of a 100-ton smart manufacturing facility in Zhuhai in 2023, which adheres to international standards and features advanced automation. Readline has successfully secured multiple rounds of funding, including a Series C round in February 2025 from investors such as CoStone Capital and Green Pine Capital Partners. These funds are intended for the development of new production bases and the enhancement of current manufacturing capabilities. The company's R&D team constitutes over 60% of its workforce, with a significant portion holding advanced degrees, underscoring its commitment to research-driven development.